GAG
KRSA

Goodman Advisory Group’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Goodman Advisory Group’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed – – 164
2022
Q4 		$0 Hold
3
– – ﹤0.01% 147
2022
Q3 		$0 Buy
+3
New +$52 ﹤0.01% 162

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goodman Advisory Group's KRSA Position: Q1 2023 in Review

Goodman Advisory Group sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2023, closing a stake of 3 shares.

Goodman Advisory Group first reported a position in KRSA in Q3 2022 and held it in 2 quarters. The position peaked at $0 in Q4 2022. 30 funds tracked by Wall St. Rank hold KRSA as of Q1 2023.

  • Goodman Advisory Group reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Goodman Advisory Group sold 3 Korsana Biosciences, Inc. Common Stock shares in Q1 2023.
  • Goodman Advisory Group first reported a position in Korsana Biosciences, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Goodman Advisory Group's Korsana Biosciences, Inc. Common Stock position peaked at $0 in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2023.

Based on Goodman Advisory Group's 13F filing for Q1 2023, filed 15 May 2023.